10 20 30 40 50 60 70 80 2L6T - Header ----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----| Asymmetric UnitHEADER ANTIVIRAL PROTEIN 24-NOV-10 2L6T
TITLE EFFICACY OF AN HIV-1 ENTRY INHIBITOR TARGETING THE GP41 FUSION PEPTIDE
COMPND MOL_ID: 1; COMPND 2 MOLECULE: VIR-576; COMPND 3 CHAIN: A; COMPND 4 ENGINEERED: YES
SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES
KEYWDS ANTI-VIRAL POLYPEPTIDE, GP41 FUSION PEPTIDE, FP1-24, ANTIVIRAL KEYWDS 2 PROTEIN
EXPDTA SOLUTION NMR
NUMMDL 14
AUTHOR W.FORSSMANN,Y.THE,M.STOLL,K.ADERMANN,U.ALBRECHT,K.BARLOS,A.BUSMANN, AUTHOR 2 A.CAN LES-MAYORDOMO,G.GIMENEZ-GALLEGO,J.HIRSCH,J.JIMENEZ-BARBERO, AUTHOR 3 D.MEYER-OLSON,J.MUENCH,J.PEREZ-CASTELLS,L.STAENDKER,F.KIRCHHOFF, AUTHOR 4 R.E.SCHMIDT
REVDAT 1 19-JAN-11 2L6T 0
JRNL AUTH W.G.FORSSMANN,Y.H.THE,M.STOLL,K.ADERMANN,U.ALBRECHT, JRNL AUTH 2 K.BARLOS,A.BUSMANN,A.CANALES-MAYORDOMO,G.GIMENEZ-GALLEGO, JRNL AUTH 3 J.HIRSCH,J.JIMENEZ-BARBERO,D.MEYER-OLSON,J.MUNCH, JRNL AUTH 4 J.PEREZ-CASTELLS,L.STANDKER,F.KIRCHHOFF,R.E.SCHMIDT JRNL TITL SHORT-TERM MONOTHERAPY IN HIV-INFECTED PATIENTS WITH A VIRUS JRNL TITL 2 ENTRY INHIBITOR AGAINST THE GP41 FUSION PEPTIDE. JRNL REF SCI TRANSL MED V. 2 63RE3 2010 JRNL REFN JRNL PMID 21178138 JRNL DOI 10.1126/SCITRANSLMED.3001697
REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH J.MUENCH,L.STAENDKER,K.ADERMANN,A.SCHULZ,M.SCHINDLER, REMARK 1 AUTH 2 R.CHINNADURAI,S.POHLMANN,C.CHAIPAN,T.BIET,T.PETERS,B.MEYER, REMARK 1 AUTH 3 D.WILHELM,H.LU,W.JING,S.JIANG,W.FORSSMANN,F.KIRCHHOFF REMARK 1 TITL DISCOVERY AND OPTIMIZATION OF A NATURAL HIV-1 ENTRY REMARK 1 TITL 2 INHIBITOR TARGETING THE GP41 FUSION PEPTIDE. REMARK 1 REF CELL(CAMBRIDGE,MASS.) V. 129 263 2007 REMARK 1 REFN ISSN 0092-8674 REMARK 1 PMID 17448989 REMARK 1 DOI 10.1016/J.CELL.2007.02.042
REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE.
REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : AMBER 9.0 REMARK 3 AUTHORS : CASE, DARDEN, CHEATHAM, III, SIMMERLING, WANG, REMARK 3 DUKE, LUO, ... AND KOLLM REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4 REMARK 4 2L6T COMPLIES WITH FORMAT V. 3.20, 01-DEC-08
REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 07-DEC-10. REMARK 100 THE RCSB ID CODE IS RCSB102029.
REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 298 REMARK 210 PH : 2.2 REMARK 210 IONIC STRENGTH : 20 SODIUM ACETATE-D3 REMARK 210 PRESSURE : AMBIENT REMARK 210 SAMPLE CONTENTS : 0.05 MM VIR-576, 0.1 MM FP1-24, REMARK 210 8 % [U-100% 2H] DMSO, 20 MM [U- REMARK 210 100% 2H] SODIUM ACETATE, 90% H2O/ REMARK 210 10% D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 2D 1H-1H NOESY; 2D 1H-1H TOCSY REMARK 210 SPECTROMETER FIELD STRENGTH : 600 MHZ; 800 MHZ REMARK 210 SPECTROMETER MODEL : AVANCE REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : XEASY, XWINNMR, CYANA REMARK 210 METHOD USED : SIMULATED ANNEALING REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 20 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 14 REMARK 210 CONFORMERS, SELECTION CRITERIA : STRUCTURES WITH THE LOWEST ENERGY REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: NULL
REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS.
REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA.
REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O PRO A 9 H GLU A 11 2.02 REMARK 500 O CYS A 6 H ILE A 8 2.11 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 CYS A 6 75.98 -111.22 REMARK 500 1 SER A 7 45.78 -81.77 REMARK 500 1 GLU A 11 -37.36 -139.48 REMARK 500 2 SER A 7 39.84 -70.40 REMARK 500 2 PRO A 10 80.66 -65.91 REMARK 500 2 GLU A 11 -47.11 -149.76 REMARK 500 3 SER A 7 77.84 -110.64 REMARK 500 3 GLU A 11 -37.91 -137.19 REMARK 500 3 PHE A 14 65.05 -118.45 REMARK 500 4 PRO A 10 84.90 -69.83 REMARK 500 4 GLU A 11 -55.66 -149.85 REMARK 500 4 PHE A 14 16.67 -141.95 REMARK 500 5 PRO A 10 90.94 -67.65 REMARK 500 5 GLU A 11 -48.80 -155.52 REMARK 500 7 PRO A 10 79.05 -67.70 REMARK 500 7 GLU A 11 -49.99 -145.31 REMARK 500 7 VAL A 19 46.37 -142.73 REMARK 500 8 GLU A 11 -41.98 -143.46 REMARK 500 9 PRO A 10 95.38 -67.00 REMARK 500 9 GLU A 11 -41.97 -162.70 REMARK 500 10 ALA A 3 46.75 -78.72 REMARK 500 10 GLU A 11 -51.69 -131.07 REMARK 500 11 GLU A 11 -52.49 -136.78 REMARK 500 11 VAL A 19 40.39 -87.43 REMARK 500 13 GLU A 2 47.06 -84.28 REMARK 500 13 SER A 7 24.48 -142.72 REMARK 500 13 PRO A 10 73.62 -68.52 REMARK 500 14 SER A 7 41.15 -102.30 REMARK 500 14 LEU A 13 -71.86 -78.43 REMARK 500 14 LYS A 16 69.27 30.72 REMARK 500 14 PRO A 17 89.57 -69.72 REMARK 500 REMARK 500 REMARK: NULL
REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2JNR RELATED DB: PDB REMARK 900 RELATED ID: 2L6S RELATED DB: PDB
REMARK 999 REMARK 999 SEQUENCE REMARK 999 VIR-576 IS A NEW POLYPEPTIDE DESIGNED ON THE BASIS OF VIRIP [CELL REMARK 999 129 (2007) 263], A NATURAL POLYPEPTIDE THAT BINDS TO THE GP41 REMARK 999 FUSION PEPTIDE OF HIV-1 PREVENTS THE VIRUS FROM ENTERING TARGET REMARK 999 CELLS. VIR-576 WAS SELECTED AFTER A LONG SCREENING PROCESS BECAUSE REMARK 999 IT SHOWS A CONSIDERABLE ENHANCED ACTIVITY.
DBREF 2L6T A 1 20 PDB 2L6T 2L6T 1 20
SEQRES 1 A 20 LEU GLU ALA ILE PRO CYS SER ILE PRO PRO GLU PHE LEU SEQRES 2 A 20 PHE GLY LYS PRO PHE VAL PHE
CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 1.000000 0.000000 0.000000 0.00000
SCALE2 0.000000 1.000000 0.000000 0.00000
SCALE3 0.000000 0.000000 1.000000 0.00000